Cercano Capital
Facts
- HQ
- United States
- Sectors
- Venture / Investment
Accipiter Bio raises $10.5M more to speed AI-designed multi-target protein drugs, expanding clinical pipeline
Seattle biotech Accipiter Bio raised an additional $10.5 million from existing investors to accelerate development of AI-designed multi-target protein therapeutics and expand its team and clinical pipeline. The company, now 22 people strong and partnered with Pfizer and Kite/Gilead, will use the funds to advance three to four programs—focusing mainly on immunology alongside oncology—after emerging from stealth last year with $12.7 million.
Seattle’s Accipiter Bio Raises $12.7M, Partners with Pfizer and Kite Pharma to Advance AI-Designed Multi-Target Protein Therapies
Seattle biotech startup Accipiter Biosciences, founded by researchers from Nobel laureate David Baker's lab, secured $12.7 million and partnerships with Pfizer and Kite Pharma to develop AI-designed multi-target proteins aiming to improve disease treatment efficacy and reduce clinical trial costs.
Seattle AI Startup Yoodli Raises $13.7M to Enhance Sales Pitch Training with Generative AI
Seattle-based AI startup Yoodli raised $13.7 million to advance its generative AI platform that helps sales teams practice pitches by simulating conversations and providing communication feedback. Founded in 2021 by Varun Puri and Esha Joshi, Yoodli serves companies like Databricks and RingCentral and partners with Toastmasters and Korn Ferry.
